We to investigate the role of amylin in newborn infants with feed intolerance which could potentially form the basis of a subsequent clinical trial. Research question: Is amylin elevated in neonates with feed intolerance (delayed gastric emptying)? Aims and Objectives: 1. To determine reference of amylin at birth (umbilical cord) and at 5-7 days (Guthrie) in term and preterm neonates (Study A). 2. To determine amylin levels in IMDM (Study B). 3. To determine amylin in preterm neonates with feed intolerance (study C). design: Prospective observational and case-control study to be conducted simultaneously as 3 sub-studies. Study A- To establish normal ranges of cord and postnatal amylin levels, mothers will be recruited antenatally for umbilical cord blood and inpatient Guthrie blood. Study B- All infants of diabetic mothers will be recruited for cord bloods, Guthrie bloods, and opportunistic bloods taken at the time of routine glucose measurement. Study Preterm infants admitted to neonatal intensive care unit and requiring tube feeding will be recruited. Amylin levels of feed intolerant infants (case) will be compared to feed tolerant infants (control) population: Study A-Term and preterm infants > 24 weeks of gestation, Study B-Term IMDM and preterm IMDM > 24 weeks of gestation and Study Preterm infants > 24 weeks of gestation Exclusion Criteria Infants born less than 24 weeks gestation Congenital malformation Chromosomal anomaly Structural gastrointestinal abnormalities and necrotising enterocolitis Haemoglobin less than 7 g/dl Breast feeding where feed volume cannot be determined Primary outcome measure: Serum amylin levels (pmol/l)
We to investigate the role of amylin in newborn infants with feed intolerance which could potentially form the basis of a subsequent clinical trial. Research question: Is amylin elevated in neonates with feed intolerance (delayed gastric emptying)? Aims and Objectives: 1. To determine reference of amylin at birth (umbilical cord) and at 5-7 days (Guthrie) in term and preterm neonates (Study A). 2. To determine amylin levels in IMDM (Study B). 3. To determine amylin in preterm neonates with feed intolerance (study C). design: Prospective observational and case-control study to be conducted simultaneously as 3 sub-studies. Study A- To establish normal ranges of cord and postnatal amylin levels, mothers will be recruited antenatally for umbilical cord blood and inpatient Guthrie blood. Study B- All infants of diabetic mothers will be recruited for cord bloods, Guthrie bloods, and opportunistic bloods taken at the time of routine glucose measurement. Study Preterm infants admitted to neonatal intensive care unit and requiring tube feeding will be recruited. Amylin levels of feed intolerant infants (case) will be compared to feed tolerant infants (control) population: Study A-Term and preterm infants > 24 weeks of gestation, Study B-Term IMDM and preterm IMDM > 24 weeks of gestation and Study Preterm infants > 24 weeks of gestation Exclusion Criteria Infants born less than 24 weeks gestation Congenital malformation Chromosomal anomaly Structural gastrointestinal abnormalities and necrotising enterocolitis Haemoglobin less than 7 g/dl Breast feeding where feed volume cannot be determined Primary outcome measure: Serum amylin levels (pmol/l)
AmylinDissertationFinalNovember2012.docx